

Supplementary Table S6: Clinical variable values comparing patients with PD-1 blockade to those with PD-L1 blockade.

	All patients N=114 (100%)	PD-1 inhibitor therapy n=57 (100%)	PD-L1 inhibitor therapy n=57 (100%)
Patient characteristics			
Sex			
male	82 (72%)	40 (70%)	42 (74%)
female	32 (28%)	17 (30%)	15 (26%)
Age			
< 70	40 (35%)	19 (33%)	21 (37%)
≥ 70	74 (65%)	38 (67%)	36 (63%)
Overall performance status (ECOG)			
0	64 (56%)	32 (56%)	32 (56%)
≥1	49 (43%)	25 (44%)	24 (42%)
Immunosuppression			
no	92 (81%)	44 (77%)	48 (84%)
yes	22 (19%)	13 (23%)	9 (16%)
LDH			
normal	43 (38%)	21 (37%)	22 (39%)
elevated	67 (59%)	35 (61%)	32 (56%)
CRP			
normal	30 (26%)	11 (19%)	19 (33%)
elevated	55 (48%)	27 (47%)	28 (49%)
NLR			
< 4	54 (47%)	22 (39%)	32 (56%)
≥ 4	35 (31%)	17 (30%)	18 (32%)
Tumor characteristics			
Localization of primary			
head and neck	24 (21%)	11 (19%)	13 (23%)
extremities	44 (39%)	17 (30%)	27 (47%)
trunk	19 (17%)	7 (12%)	12 (21%)
unknown	15 (13%)	10 (18%)	5 (9%)
Metastatic stage (AJCC)			
M0	17 (15%)	3 (5%)	14 (25%)
M1a	36 (32%)	21 (37%)	15 (26%)
M1b/M1c	61 (53%)	33 (58%)	28 (49%)
Organs involved			
1	51 (45%)	26 (46%)	25 (44%)
> 1	63 (55%)	31 (54%)	32 (56%)
MCPyV status (tumor)			
negative	10 (9%)	5 (9%)	5 (9%)
positive	32 (28%)	24 (42%)	8 (14%)
n.d.	72 (63%)	28(49%)	44 (77%)
PD-L1 (tumor)			
negative	17 (15%)	10 (17%)	7 (12%)
positive	21 (18%)	13 (23%)	8 (14%)
n.d.	76 (67%)	34 (60%)	42 (74%)
Therapeutic interventions			
Previous radiotherapy			
no	55 (48%)	24 (42%)	31 (54%)
yes	59 (52%)	33 (58%)	26 (46%)
Previous chemotherapy			
no	83 (73%)	38 (67%)	45 (79%)
yes	31 (27%)	19 (33%)	12 (21%)
Therapy response			
CR	24 (21%)	13 (23%)	11 (19%)
PR	30 (26%)	19 (33%)	11 (19%)
SD	20 (18%)	9 (16%)	11 (19%)
PD	40 (35%)	16 (28%)	24 (43%)

Abbreviations: AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; MCPyV, Merkel cell polyomavirus; NLR, neutrophil to lymphocyte ratio.